On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
FridayJan 17, 2020 12:16 pm

QualityStocksNewsBreaks – Pressure BioSciences, Inc.’s (PBIO) Innovative UST Platform Featured in Leading North American Cannabis Publication

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that its new and innovative Ultra Shear Technology(TM) (“UST”) platform was featured in Cannabis Brightline, one of North America's leading cannabis publications. Per the update, Focus Media Group (“FMG”) of Halifax, NS, Canada wrote and published the article. “This article highlights a critical issue facing the cannabis market today: the low bioavailability of CBD from CBD-infused products,” Jason Ellis, president of Vegas CBD Factory and recognized expert in the…

Continue Reading

ThursdayJan 16, 2020 3:15 pm

QualityStocksNewsBreaks – Zacks Small Cap Research Issues Update, Maintains Price Target on Pressure BioSciences Inc. (PBIO)

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform-technology solutions to the life sciences and other industries, was recently covered in a research report by Zacks Small Cap Research, a division of Zacks Investment Research. Among other highlights, Zacks maintained its $4.44 share price target on shares of PBIO. An article discussing the company reads, “The Zacks report (http://ibn.fm/z1W3H) points to demand that ‘is expected to accelerate starting in 2020,’ which nonetheless follows many years of consistent yearly revenue increases by PBIO. The company itself is standing by its stated…

Continue Reading

ThursdayJan 09, 2020 12:53 pm

QualityStocksNewsBreaks – Pressure BioSciences, Inc. (PBIO) Announces Second Straight Year of Strong Publication Numbers of Scientific Papers Citing Advantages of its PCT Platform

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that in 2019 - for the second straight year - over 20 scientific papers highlighting the advantages of PBI's patented pressure cycling technology ("PCT") platform were published worldwide. The publications, authored by independent scientists from academia, government, and industry, highlighted the powerful and enabling benefits of the PCT Platform in such critical areas as cancer research, food safety, and proteomics. “PCT-related scientific papers published in 2019 highlighted new and/or improved…

Continue Reading

ThursdayJan 02, 2020 12:01 pm

Zacks Maintains Strong $4.44 Price Target for Pressure BioSciences Inc. (PBIO)

Zacks has reiterated support for their initial $4.44 share price target for Pressure BioSciences PBIO’s fundamentals remain strong, with record sales of consumables and increased revenue from products and services over same quarter previous year Company anticipates doubling of total revenue in 2020, driven by anticipated sales of their proprietary BaroShear K45 System, which provides the CBD market with much-needed, superior water-soluble nanoemulsions of CBD Oil Zacks Small Cap Research, a division of Zacks Investment Research, has announced that they are maintaining their strong $4.44 share price target originally stated in their initial coverage of Pressure BioSciences Inc. (OTCQB: PBIO),…

Continue Reading

ThursdayDec 19, 2019 12:00 pm

QualityStocksNewsBreaks – Pressure BioSciences, Inc. (PBIO) Reports Q3 2019 Financial Results, Provides Business Update

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, services, and platform solutions to the worldwide life sciences industry, today announced financial results for the third quarter ended September 30, 2019, provided a business update and offered limited guidance for FY2020. “We have consistently highlighted the importance of the “razor/razor blade” business model.  In the 3rd quarter, consumable sales for our pressure cycling technology (“PCT”) platform exceeded $100,000/quarter for the first time, increasing by 158% over the same quarter last year,” PBI President and CEO Richard T. Schumacher said in the news…

Continue Reading

WednesdayDec 18, 2019 10:36 am

QualityStocksNewsBreaks – Pressure BioSciences, Inc. (PBIO) to Host Teleconference to Discuss Q3 2019 Financial Results, Provide Business Update

Pressure BioSciences (OTCQB: PBIO) (“PBI”) today announced that it will host a teleconference to discuss its third quarter 2019 financial results and to provide a business update. According to the update, Pressure BioSciences will include in the discussion progress made in its development of instrumentation for the nanoemulsification of oil and water. The call is scheduled to be held at 4:30 PM ET on Thursday, December 19, 2019. Interested parties may join the teleconference by dialing (844) 602-0380 (North America) or (862) 298-0970 (International) and providing passcode: PBI Third Quarter 2019 Financial Call & Business Update. For those unable to…

Continue Reading

WednesdayOct 23, 2019 3:14 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) PCT Platform Highlighted at IGCS Conference in Brazil

Pressure BioSciences’ (OTCQB: PBIO) patented pressure cycling technology (“PCT”) platform was recently described as an integral part of women’s cancer research efforts during a presentation at the International Gynecologic Cancer Society conference in Brazil. An article discussing the company reads, “Pressure BioSciences’ PCT platform, as an integral part of the analytical trio, prepares the excised cells for micro-scale quantitative proteomics and phosphoproteomics – the large-scale study of proteins and their phosphorylation-based signaling networks – by provoking rapid and efficient high-quality cellular protein release and preparation from the biopsy samples. The entire sample preparation process is done in the company’s proprietary…

Continue Reading

MondayOct 14, 2019 3:32 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) Proprietary PCT Platform Demonstrates Ability to Discover Cancer Biomarkers in Independent Research

Pressure BioSciences’ (OTCQB: PBIO) pressure cycling technology (“PCT”) platform was recently the subject of independent research carried out by Chinese and Australian scientists in which the platform demonstrated its proficiency in processing of preserved (“FFPE”) and fresh frozen biopsy tissue samples for the discovery of cancer biomarkers (http://ibn.fm/DfmC7). An article discussing the company reads, “According to Pressure BioSciences president and CEO Richard T. Schumacher, over one billion archival tissue samples exist in pathology and other laboratories across the world. Millions of additional samples are processed and stored every single year. These samples contain an abundance of information that could be…

Continue Reading

ThursdayOct 10, 2019 2:48 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) BaroShear K45 System Creates Water-Soluble CBD Oil

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, has developed a revolutionary CBD processing system, the BaroShear K45, which effectively solves the water solubility issue found in most of today’s oil-based CBD products. An article discussing the company reads, “Development of the BaroShear K45 system began following the company’s in-depth analysis of the CBD market, which showed a common, yet critical production issue facing CBD manufacturers – the poor water solubility of today’s oil-based CBD products means that the beneficial properties of…

Continue Reading

FridayOct 04, 2019 12:14 pm

Pressure BioSciences Inc. (PBIO) Gains Praise Amid Disclosure of Innovative Research Tool to Aid Gynecological Cancer Diagnosis, Therapy

Pressure BioSciences was described as an integral part of women’s cancer research efforts during a presentation last month at the International Gynecologic Cancer Society conference in Brazil The company’s patented pressure cycling technology provided a key link in a trio of procedures for analyzing biopsied cells Gynecologic cancers are diagnosed in the United States at a rate of nearly 100,000 women per year, and the global gynecological cancer drug market is expected to generate revenues of more than $41.8 billion by 2026 A new, novel workflow for the analysis of proteins from cancer biopsy samples was recently disclosed at a…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered